230618-41-4

Basic information

• Product Name: 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE
• Synonyms: 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE;2-Bromo-6-pyrrolidin-1-ylpyridine 97%;(6-Bromopyridin-2-yl)pyrrolidine;2-Bromo-6-pyrrolidin-1-ylpyridine97%
• CAS NO: 230618-41-4
• Molecular Formula: C₉H₁₁BrN₂
• Molecular Weight: 227.1
• Product Categories: Amines;blocks;Bromides;Pyridines;Halides;alkyl bromide
• Mol File: 230618-41-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 86 °C
• Boiling Point: 335.5°Cat760mmHg
• Flash Point: 156.7°C
• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.597
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE(230618-41-4)
• EPA Substance Registry System: 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE(230618-41-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 230618-41-4(Hazardous Substances Data)

Usage

General Description

2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE is a chemical compound with the molecular formula C11H14BrN3. It is a pyridine derivative that contains a pyrrolidin-1-yl group and a bromine atom. 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE has potential applications in the pharmaceutical industry, particularly in drug discovery and development. Its unique structure makes it an interesting target for medicinal chemistry research, as it may exhibit biological activity that could be beneficial for the treatment of certain medical conditions. Further studies are needed to fully understand the properties and potential uses of 2-BROMO-6-PYRROLIDIN-1-YLPYRIDINE.

InChI:InChI=1/C9H11BrN2/c10-8-4-3-5-9(11-8)12-6-1-2-7-12/h3-5H,1-2,6-7H2

Upstream product

• 109-96-6 3-Pyrroline 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 626-05-1 2,6-Dibromopyridine 
• 123-75-1 pyrrolidine 

Downstream Products

• 877201-65-5 2-(3-nitrophenyl)-6-(pyrrolidin-1-yl)pyridine 
• 1220595-95-8 benzyl 2-(6-(pyrrolidin-1-yl)pyridin-2-yl)ethylcarbamate 
• 1309609-57-1 2-(4-methoxyphenyl)-6-(pyrrolidin-1-yl)pyridine 
• 1309609-81-1 N,N-dimethyl-4-(6-(pyrrolidin-1-yl)pyridin-2-yl)aniline 
• 1309609-48-0 2-phenyl-6-(pyrrolidin-1-yl)pyridine 
• 877202-74-9 PSNCBAM-1 

Relevant articles and documents

Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)

Undesirable side effects associated with orthosteric agonists/antagonists of cannabinoid 1 receptor (CB1R), a tractable target for treating several pathologies affecting humans, have greatly limited their translational potential. Recent discovery of CB1R negative allosteric modulators (NAMs) has renewed interest in CB1R by offering a potentially safer therapeutic avenue. To elucidate the CB1R allosteric binding motif and thereby facilitate rational drug discovery, we report the synthesis and biochemical characterization of first covalent ligands designed to bind irreversibly to the CB1R allosteric site. Either an electrophilic or a photoactivatable group was introduced at key positions of two classical CB1R NAMs: Org27569 (1) and PSNCBAM-1 (2). Among these, 20 (GAT100) emerged as the most potent NAM in functional assays, did not exhibit inverse agonism, and behaved as a robust positive allosteric modulator of binding of orthosteric agonist CP55,940. This novel covalent probe can serve as a useful tool for characterizing CB1R allosteric ligand-binding motifs.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [3H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emaxof the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.

FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS

A series of quinoxaline derivatives, and analogues thereof, which are functionalised further by a substituted phenyl or pyridinyl moiety, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.